BALTIMORE, MD — Personal Genome Diagnostics Inc. (PGDx), a leading provider of advanced cancer genome testing products and services, today announced an agreement with Illumina, Inc. (NASDAQ: ILMN) to develop two in-vitro diagnostic (IVD) test kits for use on Illumina’s sequencing instruments, including kits for the detection and characterization of tumor DNA using both tissue and plasma samples.

Doug Ward, Chief Executive Officer of PGDx, noted, “PGDx currently offers advanced genomic testing

services to researchers, drug developers, and physicians and patients through our CLIA-certified

laboratory. We now want to apply our expertise to the development of IVD test kits for both tissue and

plasma-based samples that will enable other laboratories with next-generation sequencing (NGS) capability to benefit from our broad experience in cancer genomic testing. Illumina is universally recognized as the global leader in NGS platforms, and we are delighted to join forces with them to